Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1706

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 15
Chunk 1706
---
			Balance - September 30, 2025

			378,039

			$
			24.70

			$
			18.12

There were no options exercised during the years ended September 30, 2025 or September 30, 2024. The intrinsic value of options outstanding at September 30, 2025 was $0.00.

The weighted average contractual life remaining on the outstanding options at September 30, 2025 is 68 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at September 30, 2025:

			Number of Options

			Exercisable at
			September 30, 2025 (#) 

			Range of Exercise Prices 

			Expiry Dates

			37,719

			37,719

			C$
			15.12

			August 2027 - Dec 2028

			43,031

			43,031

			$
			22.12

			Feb 2030

			51,006

			51,006

			$
			52.08 - 56.49

			September 2030 - Oct 2030

			79,651

			79,651

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			56,865

			56,865

			$
			25.97

			March 2025 - Feb 2032

			109,767

			91,887

			$
			4.10 - 10.01

			March 2025 - Oct 2033

			378,039

			360,159

The options exercisable at September 30, 2025 had a weighted average exercise price of $25.59 and an intrinsic value of $0.00 and a weighted average remaining life of 67 months. There were 17,880 options at September 30, 2025 that had not vested with a weighted average exercise price of $6.77 and an intrinsic value of $0.00 and a weighted average remaining life of 91 months.

F-18

EDESA BIOTECH, INC.

Notes to Consolidated Financial Statements

For the Years Ended September 30, 202